Prosecution Insights
Last updated: October 23, 2026
Application No. 19/029,629

DEPLOYMENT MARKER

Non-Final OA §101§102
Filed
Jan 17, 2025
Priority
Feb 27, 2017 — provisional 62/464,202 +4 more
Examiner
REMALY, MARK DONALD
Art Unit
Tech Center
Assignee
Boston Scientific Corporation
OA Round
1 (Non-Final)
70%
Grant Probability
Favorable
1-2
OA Rounds
1y 10m
Est. Remaining
86%
With Interview

Examiner Intelligence

Grants 70% — above average
70%
Career Allowance Rate
519 granted / 736 resolved
+10.5% vs TC avg
Strong +16% interview lift
Without
With
+15.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
21 currently pending
Career history
751
Total Applications
across all art units

Statute-Specific Performance

§101
7.5%
-32.5% vs TC avg
§103
39.6%
-0.4% vs TC avg
§102
21.2%
-18.8% vs TC avg
§112
28.6%
-11.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 736 resolved cases

Office Action

§101 §102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Double Patenting A rejection based on double patenting of the “same invention” type finds its support in the language of 35 U.S.C. 101 which states that “whoever invents or discovers any new and useful process... may obtain a patent therefor...” (Emphasis added). Thus, the term “same invention,” in this context, means an invention drawn to identical subject matter. See Miller v. Eagle Mfg. Co., 151 U.S. 186 (1894); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Ockert, 245 F.2d 467, 114 USPQ 330 (CCPA 1957). A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the claims that are directed to the same invention so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101. Claim 1 is provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claim 1 of copending Application No. 18/930,176 (reference application). This is a provisional statutory double patenting rejection since the claims directed to the same invention have not in fact been patented. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Riedy et al. (US 2016/0242943 A1). Regarding claim 1, Riedy et al. (‘943) teach a stent delivery system, comprising: a catheter comprising a primary marker and at least one secondary marker (see [0016]-[0017], [0018], [0021]), wherein the at least one secondary marker is disposed within the primary marker (see [0023]-[0025]); an inner catheter slidably disposed within a lumen of the catheter, wherein the catheter can be retracted relative to the inner catheter such that a portion of the inner catheter extends from a distal end of the catheter (see [0016]-[0017]); and a stent disposed over the portion of the inner catheter, wherein the stent is constrained to a collapsed configuration when the inner catheter is disposed in the lumen of the catheter and expands to an expanded configuration when the portion of the inner catheter extends from the distal end of the catheter, wherein the stent comprises a distal retention member and a proximal retention member when in the expanded configuration (see [0016]-[0018]), and wherein the secondary marker is positioned with respect to the primary marker such that confirmation within the body lumen of the secondary marker denotes that the entire proximal retention member is deployable proximally relative to a reference position (see [0016]-[0017], [0018], [0021]), [0023]-[0025]). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARK REMALY whose telephone number is (571)270-1491. The examiner can normally be reached Mon - Fri 9:00 - 6:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Christopher Koharski can be reached at (571) 272-7230. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MARK D REMALY/Primary Examiner, Art Unit 3797
Read full office action

Prosecution Timeline

Jan 17, 2025
Application Filed
Oct 05, 2026
Non-Final Rejection mailed — §101, §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758328
METHOD AND SYSTEM FOR ESTIMATING POSITIONAL DATA IN IMAGES
1y 3m to grant Granted Oct 13, 2026
Patent 12751688
ULTRASOUND VISUALIZATION DEVICE
3y 7m to grant Granted Oct 06, 2026
Patent 12751692
ASSESSING HEART PARAMETERS USING NEURAL NETWORKS
1y 8m to grant Granted Oct 06, 2026
Patent 12751776
ACTIVE ROBOTIC PIN PLACEMENT IN TOTAL KNEE ARTHROPLASTY
1y 6m to grant Granted Oct 06, 2026
Patent 12746094
MARKING DEVICE AND IMPLANTATION SYSTEM
1y 10m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
70%
Grant Probability
86%
With Interview (+15.9%)
3y 8m (~1y 10m remaining)
Median Time to Grant
Low
PTA Risk
Based on 736 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month